Disease processes often involve cross-talks between proteins in different pathways. Different proteins have been used as separate therapeutic targets for the same disease. Synergetic targeting of multiple targets has been explored in combination therapy of a number of diseases. Cross-links to other databases are also introduced to facilitate the access of information about individual pathways and proteins. This database can be accessed at
Introduction
Proteins and nucleic acids that play key roles in disease processes have been explored as therapeutic targets for drug development (Drews, 2000; Ohlstein et al., 2000) . Knowledge of these therapeutically relevant proteins and nucleic acids has facilitated modern drug discovery by providing platforms for drug screening against a pre-selected target (Drews, 2000) . It has also contributed to the study of the molecular mechanism of drug actions, discovery of new therapeutic targets, and development of drug design tools (Hopkins and Groom, 2002; Zambrowicz and Sands, 2003) . Information about non-target proteins and natural small molecules involved in these pathways is also useful for facilitating the search of new therapeutic targets and for understanding how therapeutic targets interact with other molecules to perform specific tasks.
A number of web-based resources of therapeutically-targeted proteins and nucleic acids are available (Chen et al., 2002; Ji et al., 2003) , which provide useful information about the targets of drugs and investigational agents. Cross-talks between proteins of different pathways are common phenomena and these often have therapeutic implications (Abdel-Latif, 1996; Adcock and Caramori, 2001; Alaoui-Jamali and Qiang, 2003; Ignar-Trowbridge et al., 1992; Kumar-Sinha et al., 2002; Minatoguchi et al., 2003; Takayanagi et al., 2000; Zemel, 1998) . Cocktail drug combination therapies directed at multiple targets have been explored for a number of diseases including AIDS (Grodesky et al., 2001) , cancer (El-Rayes and Philip, 2002; Sagae et al., 2003) , Alzheimer disease (Tariot and Federoff, 2003) , amyotrophic lateral sclerosis (Kriz et al., 2003) , and dyslipidemia (Bays and Stein, 2003) . These prompted interest for more extensive exploration of synergistic targeting of multiple targets in drug discovery (Huang, 2002) . Potential harmful interactions arising from multiple targeting are also closely watched and studied (Lewis, 2003) .
Effective drugs with robust phenotypic effects are known to simultaneously affect many proteins in different pathways (Huang, 2002) . For instance, in addition to interacting with its main target protein cyclooxygenase, anti-inflammatory drug salicylate is known to affect NF-kB pathway and other connected cellular targets that all normally contribute to perpetuate inflammatory state (Alpert and Vilcek, 2000; Yin et al., 1998) . Therefore resources of therapeutically relevant multiple pathways 4 are useful for facilitating the analysis of the potential implications of multiple target-based therapies and for mechanistic study of drug effects.
Pathway information can be obtained or extracted from various internet pathway databases and protein databases. These include Expasy Biochemical pathways (http://www.expasy.ch/cgi-bin/search-biochem-index) (Gasteiger et al., 2003) (Bader et al., 2003) , TRANSPATH (http://www.biobase.de/pages/products/databases.html) (Krull et al., 2003) , and Signal transduction knowledge environment (http://stke.sciencemag.org/index.dtl) (Gough, 2001) .
While information about multiple pathways can be obtained from the existing individual pathway databases, interfaces that integrate multiple pathway maps may provide more convenient platforms for facilitating the analysis of the collective effects of different proteins in separate pathways.
Moreover, the existing databases either include significantly more number of pathways than therapeutic ones or they are intended for specific types of pathways that do not cover all of the therapeutic ones, which can sometimes make the search of therapeutically relevant constituents less convenient. It is thus desirable to have a database specifically designed as a convenient source of information about therapeutically relevant multiple pathways to complement existing databases.
In this work, we introduce a Therapeutically Relevant Multiple Pathway (TRMP) database, which gives information about inter-related multiple pathways of a number of diseases and physiological processes. This database provides information about known therapeutic targets within each network of multiple pathways, the corresponding drugs/ligands directed at each of these targets, the constituent individual pathways, and information about the proteins involved in these pathways.
Cross-links to other databases are introduced to facilitate the access of information about the constituent individual pathways and the function, sequence, nomenclature, and related literatures of each protein in the pathways.
Database structure and access
TRMP can be accessed at http://bidd.nus.edu.sg/group/trmp/trmp.asp and it can be downloaded upon written request. The use of this database is free for con-commercial purposes. The entries of this database are generated by using the information collected from a comprehensive search of related publications in MEDLINE (Wheeler et al., 2003) . Combination of three keywords (disease name, target name, and "pathway") is used in searching the relevant publications. The relevant information is derived primarily from review articles and pharmacology textbooks. Primary articles are also used for clarification purpose. The extracted information is double checked against the referenced articles independently by different persons. All of the references used for generating the pathways are provided in the database. Human data are used for human pathways and proteins. Likewise, the corresponding species data are used for bacterial or viral pathways and proteins. TRMP is updated every 6 months.
Our approach of linking human proteins to the human pathway constituents (with the exception of the viral and bacterial specific ones) is critically based on the assumption that all of the shown pathways happen in human although this may not have been experimentally verified. The pathway models in the review articles and textbooks are often based on the results of a patchwork of 6 experimental systems involving genes and proteins of different species origin. Thus caution is needed in interpreting the molecular interactions and pathway constituents in TRMP. Effort will be paid to promptly update newly reported results to our database.
As TRMP claims to become a medical resource this may lead to dangerous misinterpretations.
Our database currently contains 11 entries of multiple pathways that include 97 distinct individual pathways and 120 therapeutic targets covering 72 different disease conditions. A total of 32 of the 97 distinct individual pathways are included in other pathway databases. The list of multiple pathways and distinct individual pathways are given in the supplementary material which also includes the related diseases, the number and examples of associated known therapeutic targets, and examples of corresponding drugs directed at these targets.
The interactive maps of each pathway entry of TRMP are constructed by using Macromedia FLASH.
The corresponding database architect associated with the pathway interactive maps is developed by using Active Server Page with Oracle 9i support. This database has three layers. The top layer is the main graphical user interface with a querying tool for finding specific entries of multiple pathways.
The second layer is the graphical interface for the interactive maps of multiple pathways with a browser tool for retrieving additional information. The browser tool can be used both for accessing information about the constituent individual pathways from other databases and for retrieving information about individual targets or non-target proteins directs a retrieving request from TRMP.
The third layer is the graphic interface for entries of individual targets or non-target proteins with a browser tool for accessing additional information from other databases.
The TRMP database web interface is shown in Figure 1 . This database is searchable by selecting the name of a particular entry of multiple-pathways. It can also be accessed by selection of the name of a disease or the name of an individual pathway from the list provided in the corresponding selection field. Searches involving any combination of these three search or selection fields are also supported. The relevant information can be accessed by clicking a yellow box which is linked to the corresponding protein information page provided in our database. Proteins in the blue boxes are those with only a general name specified in the literature which is not specific enough to determine their identity. As a result, no detailed information about these proteins is available in the current version of our database.
A small molecule ligand is represented by its name and its action of a protein is indicated by a white circular box with one of the following symbols inside. These symbols are +, -, , , P, R, B, D and A which represents activation of the protein, inhibition of the protein, increase of the protein level, decrease of the protein level, protein phosphorylation, release of the protein to extra-cellular environment, binding to the protein with unknown effect, binding to the protein leading to its dimerization, and binding to the protein as an antibody respectively. A pink circular box indicates the site and action of a drug or investigative agent and the type of drug action is represented by the same set of symbols as that for small molecule ligands. More detailed information about the corresponding drugs is represented through a mouse-over-effect upon clicking a relevant pink drug action circular box.
The names of the constituent individual pathways contained in each entry are given. Cross links to other pathway databases are provided for those individual pathways that are described in other pathway databases. The effects of the pathways are given by the green boxes with unregulated dot line which include the description about each effect. There are cases that the actual protein involved in a particular process in a pathway is unidentified. Thus, instead of the actual protein, the related 8 process is described in the same way. In addition, the complex of several proteins is demonstrated by the light-blue boxes with dot line. Figure 3 gives the interface of a target entry of TRMP, which is similar to that of a non-target protein entry with the exception that the former contain a section for potential therapeutic implications.
Information provided include protein name, synonyms, Swissprot AC number, species, gene name and location, protein sequence (AASEQ) and gene sequence (NTSEQ) as well as potential therapeutic implications while applicable. Cross-links to other databases are provided which include Genecard, GDB, Locuslink, NCBI, KEGG, OMIM and SwissProt to facilitate the access of more detailed information about various aspects of the particular target or non-target protein.
Concluding remarks
With rapid advances in proteomics (Dove, 1999) , pathways (Huang, 2002) and systems (Schwartz et al., 2000) , new information about therapeutically relevant multiple pathways can be incorporated or the corresponding databases can be cross-linked to TRMP to provide more comprehensive information about the therapeutically relevant pathways, related targets and their relationship to other biomolecules and cellular processes. 
Supplementary Material
Table1 : List of therapeutically relevant multiple pathways, covered diseases, therapeutic targets and examples of drugs in TRMP. The numbers in the brackets are the total number of multiple pathways entries, therapeutic targets and covered diseases in the database. 
